{"transactions":[{"id":997555,"issuer":{"id":73047,"kind":"organization","name":"LAVA Therapeutics NV","symbol":"LVTX"},"owners":[{"id":73055,"kind":"person","name":"Noble James","position":1,"cik":"0001388000","reported_name":"Noble James","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Share Options (Right to Buy)","published_at":"2025-11-17T16:30:17.000Z","date":"2025-11-13","kind":"disposition_to_issuer","planned":false,"acquired":false,"shares":33390,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"This option was cancelled pursuant to that certain Purchase Agreement, dated August 3, 2025, by and between the Issuer and XOMA Royalty Corporation (as amended, the \"Purchase Agreement\") in exchange for cash and contingent value rights (\"CVRs\") (without interest and net of applicable withholding tax and other applicable deductions) in an amount equal to (i) the excess of $1.04 over the per share exercise price of such option multiplied by the total number of shares underlying such in option and (ii) one CVR per share underlying such in-the-money option."}],"balance_after":0,"derivative":{"exercise_price":0.93,"expiration_date":"2035-02-12","underlying":"Common Shares","underlying_shares":33390},"source":{"system":"sec-edgar","filing":"0001388000-25-000005","document":"form4-11172025_041113.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1388000/000138800025000005/form4-11172025_041113.xml","form_type":"4"}},{"id":1263329,"issuer":{"id":73047,"kind":"organization","name":"LAVA Therapeutics NV","symbol":"LVTX"},"owners":[{"id":73055,"kind":"person","name":"Noble James","position":1,"cik":"0001388000","reported_name":"Noble James","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Shares (Right to Buy)","published_at":"2025-02-18T20:15:20.000Z","date":"2025-02-13","kind":"grant","planned":false,"acquired":true,"shares":33390,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"100% of the shares underlying the option will vest on February 13, 2026, provided the Reporting Person remains in a service relationship with the Issuer or a subsidiary of the Issuer on such vesting date."}],"balance_after":33390,"derivative":{"exercise_price":0.93,"expiration_date":"2035-02-12","underlying":"Common Shares","underlying_shares":33390},"source":{"system":"sec-edgar","filing":"0001415889-25-004530","document":"form4-02182025_080216.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1388000/000141588925004530/form4-02182025_080216.xml","form_type":"4"}},{"id":2216802,"issuer":{"id":9824,"kind":"organization","name":"Adaptimmune Therapeutics PLC"},"owners":[{"id":73055,"kind":"person","name":"Noble James","position":1,"cik":"0001388000","reported_name":"Noble James","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Option to purchase Ordinary Shares","published_at":"2022-07-01T17:02:06.000Z","date":"2022-07-01","kind":"grant","acquired":true,"shares":710711,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F1","text":"The exercise price was converted from GBP0.23 based on an exchange rate of $U.S. 1.216007 to GBP1.00. The actual exercise price will be the pounds sterling amount."}],"balance_after":710711,"derivative":{"exercise_price":0.28,"exercise_date":"2023-07-01","expiration_date":"2032-07-01","underlying":"Ordinary Shares","underlying_shares":710711},"source":{"system":"sec-edgar","filing":"0001104659-22-076897","document":"tm2220260-4_4seq1.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1388000/000110465922076897/tm2220260-4_4seq1.xml","form_type":"4"}},{"id":2643829,"issuer":{"id":9824,"kind":"organization","name":"Adaptimmune Therapeutics PLC"},"owners":[{"id":73055,"kind":"person","name":"Noble James","position":1,"cik":"0001388000","reported_name":"Noble James","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Option to purchase Ordinary Shares","published_at":"2021-07-02T17:02:23.000Z","date":"2021-07-01","kind":"grant","acquired":true,"shares":379788,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F1","text":"The exercise price was converted from GBP0.51 based on an exchange rate of $U.S. 1.3807 to GBP1.00. The actual exercise price will be the pounds sterling amount."}],"balance_after":379788,"derivative":{"exercise_price":0.71,"exercise_date":"2022-07-01","expiration_date":"2031-07-01","underlying":"Ordinary Shares","underlying_shares":379788},"source":{"system":"sec-edgar","filing":"0001104659-21-088969","document":"tm2121284-4_4seq1.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1388000/000110465921088969/tm2121284-4_4seq1.xml","form_type":"4"}},{"id":2722874,"issuer":{"id":139616,"kind":"organization","name":"GW PHARMACEUTICALS PLC","symbol":"GWPH"},"owners":[{"id":73055,"kind":"person","name":"Noble James","position":1,"cik":"0001388000","reported_name":"Noble James","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Share Options","published_at":"2021-05-07T16:15:39.000Z","date":"2021-05-05","kind":"disposition_to_issuer","acquired":false,"shares":22464,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F3","text":"Pursuant to the Transaction Agreement, these share options vested (to the extent unvested) and were canceled in connection with the closing of the transactions contemplated by the Transaction Agreement in exchange for an all-cash payment equal to the value of the share options based on the value of the transaction consideration."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F3","text":"Pursuant to the Transaction Agreement, these share options vested (to the extent unvested) and were canceled in connection with the closing of the transactions contemplated by the Transaction Agreement in exchange for an all-cash payment equal to the value of the share options based on the value of the transaction consideration."}],"balance_after":0,"derivative":{"exercise_price":0.0017,"expiration_date":"2031-02-22","underlying":"Ordinary Shares","underlying_shares":22464},"source":{"system":"sec-edgar","filing":"0000899243-21-018665","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":9,"url":"https://www.sec.gov/Archives/edgar/data/1351288/000089924321018665/doc4.xml","form_type":"4"}},{"id":2722873,"issuer":{"id":139616,"kind":"organization","name":"GW PHARMACEUTICALS PLC","symbol":"GWPH"},"owners":[{"id":73055,"kind":"person","name":"Noble James","position":1,"cik":"0001388000","reported_name":"Noble James","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Share Options","published_at":"2021-05-07T16:15:39.000Z","date":"2021-05-05","kind":"disposition_to_issuer","acquired":false,"shares":34416,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F3","text":"Pursuant to the Transaction Agreement, these share options vested (to the extent unvested) and were canceled in connection with the closing of the transactions contemplated by the Transaction Agreement in exchange for an all-cash payment equal to the value of the share options based on the value of the transaction consideration."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F3","text":"Pursuant to the Transaction Agreement, these share options vested (to the extent unvested) and were canceled in connection with the closing of the transactions contemplated by the Transaction Agreement in exchange for an all-cash payment equal to the value of the share options based on the value of the transaction consideration."}],"balance_after":0,"derivative":{"exercise_price":0.0017,"expiration_date":"2030-06-04","underlying":"Ordinary Shares","underlying_shares":34416},"source":{"system":"sec-edgar","filing":"0000899243-21-018665","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":8,"url":"https://www.sec.gov/Archives/edgar/data/1351288/000089924321018665/doc4.xml","form_type":"4"}},{"id":2722872,"issuer":{"id":139616,"kind":"organization","name":"GW PHARMACEUTICALS PLC","symbol":"GWPH"},"owners":[{"id":73055,"kind":"person","name":"Noble James","position":1,"cik":"0001388000","reported_name":"Noble James","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Share Options","published_at":"2021-05-07T16:15:39.000Z","date":"2021-05-05","kind":"disposition_to_issuer","acquired":false,"shares":9432,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F3","text":"Pursuant to the Transaction Agreement, these share options vested (to the extent unvested) and were canceled in connection with the closing of the transactions contemplated by the Transaction Agreement in exchange for an all-cash payment equal to the value of the share options based on the value of the transaction consideration."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F3","text":"Pursuant to the Transaction Agreement, these share options vested (to the extent unvested) and were canceled in connection with the closing of the transactions contemplated by the Transaction Agreement in exchange for an all-cash payment equal to the value of the share options based on the value of the transaction consideration."}],"balance_after":0,"derivative":{"exercise_price":0.0017,"expiration_date":"2029-03-01","underlying":"Ordinary Shares","underlying_shares":9432},"source":{"system":"sec-edgar","filing":"0000899243-21-018665","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":7,"url":"https://www.sec.gov/Archives/edgar/data/1351288/000089924321018665/doc4.xml","form_type":"4"}},{"id":2722871,"issuer":{"id":139616,"kind":"organization","name":"GW PHARMACEUTICALS PLC","symbol":"GWPH"},"owners":[{"id":73055,"kind":"person","name":"Noble James","position":1,"cik":"0001388000","reported_name":"Noble James","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Share Options","published_at":"2021-05-07T16:15:39.000Z","date":"2021-05-05","kind":"disposition_to_issuer","acquired":false,"shares":16548,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F3","text":"Pursuant to the Transaction Agreement, these share options vested (to the extent unvested) and were canceled in connection with the closing of the transactions contemplated by the Transaction Agreement in exchange for an all-cash payment equal to the value of the share options based on the value of the transaction consideration."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F3","text":"Pursuant to the Transaction Agreement, these share options vested (to the extent unvested) and were canceled in connection with the closing of the transactions contemplated by the Transaction Agreement in exchange for an all-cash payment equal to the value of the share options based on the value of the transaction consideration."}],"balance_after":0,"derivative":{"exercise_price":14.3342,"expiration_date":"2029-03-01","underlying":"Ordinary Shares","underlying_shares":16548},"source":{"system":"sec-edgar","filing":"0000899243-21-018665","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":6,"url":"https://www.sec.gov/Archives/edgar/data/1351288/000089924321018665/doc4.xml","form_type":"4"}},{"id":2722870,"issuer":{"id":139616,"kind":"organization","name":"GW PHARMACEUTICALS PLC","symbol":"GWPH"},"owners":[{"id":73055,"kind":"person","name":"Noble James","position":1,"cik":"0001388000","reported_name":"Noble James","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Share Options","published_at":"2021-05-07T16:15:39.000Z","date":"2021-05-05","kind":"disposition_to_issuer","acquired":false,"shares":10740,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F3","text":"Pursuant to the Transaction Agreement, these share options vested (to the extent unvested) and were canceled in connection with the closing of the transactions contemplated by the Transaction Agreement in exchange for an all-cash payment equal to the value of the share options based on the value of the transaction consideration."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F3","text":"Pursuant to the Transaction Agreement, these share options vested (to the extent unvested) and were canceled in connection with the closing of the transactions contemplated by the Transaction Agreement in exchange for an all-cash payment equal to the value of the share options based on the value of the transaction consideration."}],"balance_after":0,"derivative":{"exercise_price":0.0017,"expiration_date":"2028-01-03","underlying":"Ordinary Shares","underlying_shares":10740},"source":{"system":"sec-edgar","filing":"0000899243-21-018665","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":5,"url":"https://www.sec.gov/Archives/edgar/data/1351288/000089924321018665/doc4.xml","form_type":"4"}},{"id":2722869,"issuer":{"id":139616,"kind":"organization","name":"GW PHARMACEUTICALS PLC","symbol":"GWPH"},"owners":[{"id":73055,"kind":"person","name":"Noble James","position":1,"cik":"0001388000","reported_name":"Noble James","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Share Options","published_at":"2021-05-07T16:15:39.000Z","date":"2021-05-05","kind":"disposition_to_issuer","acquired":false,"shares":17676,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F3","text":"Pursuant to the Transaction Agreement, these share options vested (to the extent unvested) and were canceled in connection with the closing of the transactions contemplated by the Transaction Agreement in exchange for an all-cash payment equal to the value of the share options based on the value of the transaction consideration."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F3","text":"Pursuant to the Transaction Agreement, these share options vested (to the extent unvested) and were canceled in connection with the closing of the transactions contemplated by the Transaction Agreement in exchange for an all-cash payment equal to the value of the share options based on the value of the transaction consideration."}],"balance_after":0,"derivative":{"exercise_price":11.1742,"expiration_date":"2028-01-03","underlying":"Ordinary Shares","underlying_shares":17676},"source":{"system":"sec-edgar","filing":"0000899243-21-018665","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":4,"url":"https://www.sec.gov/Archives/edgar/data/1351288/000089924321018665/doc4.xml","form_type":"4"}},{"id":2722868,"issuer":{"id":139616,"kind":"organization","name":"GW PHARMACEUTICALS PLC","symbol":"GWPH"},"owners":[{"id":73055,"kind":"person","name":"Noble James","position":1,"cik":"0001388000","reported_name":"Noble James","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Share Options","published_at":"2021-05-07T16:15:39.000Z","date":"2021-05-05","kind":"disposition_to_issuer","acquired":false,"shares":9168,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F3","text":"Pursuant to the Transaction Agreement, these share options vested (to the extent unvested) and were canceled in connection with the closing of the transactions contemplated by the Transaction Agreement in exchange for an all-cash payment equal to the value of the share options based on the value of the transaction consideration."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F3","text":"Pursuant to the Transaction Agreement, these share options vested (to the extent unvested) and were canceled in connection with the closing of the transactions contemplated by the Transaction Agreement in exchange for an all-cash payment equal to the value of the share options based on the value of the transaction consideration."}],"balance_after":0,"derivative":{"exercise_price":0.0017,"expiration_date":"2027-01-06","underlying":"Ordinary Shares","underlying_shares":9168},"source":{"system":"sec-edgar","filing":"0000899243-21-018665","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1351288/000089924321018665/doc4.xml","form_type":"4"}},{"id":2722867,"issuer":{"id":139616,"kind":"organization","name":"GW PHARMACEUTICALS PLC","symbol":"GWPH"},"owners":[{"id":73055,"kind":"person","name":"Noble James","position":1,"cik":"0001388000","reported_name":"Noble James","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Share Options","published_at":"2021-05-07T16:15:39.000Z","date":"2021-05-05","kind":"disposition_to_issuer","acquired":false,"shares":18636,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F3","text":"Pursuant to the Transaction Agreement, these share options vested (to the extent unvested) and were canceled in connection with the closing of the transactions contemplated by the Transaction Agreement in exchange for an all-cash payment equal to the value of the share options based on the value of the transaction consideration."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F3","text":"Pursuant to the Transaction Agreement, these share options vested (to the extent unvested) and were canceled in connection with the closing of the transactions contemplated by the Transaction Agreement in exchange for an all-cash payment equal to the value of the share options based on the value of the transaction consideration."}],"balance_after":0,"derivative":{"exercise_price":9.8117,"expiration_date":"2027-01-06","underlying":"Ordinary Shares","underlying_shares":18636},"source":{"system":"sec-edgar","filing":"0000899243-21-018665","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1351288/000089924321018665/doc4.xml","form_type":"4"}},{"id":2722866,"issuer":{"id":139616,"kind":"organization","name":"GW PHARMACEUTICALS PLC","symbol":"GWPH"},"owners":[{"id":73055,"kind":"person","name":"Noble James","position":1,"cik":"0001388000","reported_name":"Noble James","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Ordinary Shares","published_at":"2021-05-07T16:15:39.000Z","date":"2021-05-05","kind":"disposition_to_issuer","acquired":false,"shares":27492,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"On May 5, 2021, Jazz Pharmaceuticals Public Limited Company, a public limited company incorporated in the Republic of Ireland (\"Jazz\"), Jazz Pharmaceuticals UK Holdings Limited, a private limited company incorporated in England and Wales and an indirect wholly owned subsidiary of Jazz (\"Bidco\") and the DR Nominee (as defined in the Transaction Agreement) acquired all outstanding ordinary shares, par value British Pound Sterling 0.001 per share, of GW Pharmaceuticals plc, a public limited company incorporated in England and Wales (the \"Company\"), by means of a scheme of arrangement under Part 26 of the UK Companies Act 2006 (the \"Scheme of Arrangement\") (continued in footnote 2)."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"At the effective time of the Scheme of Arrangement, Scheme Shareholders (as defined in the Scheme of Arrangement) became entitled to receive for each Scheme Share (as defined in the Scheme of Arrangement) held by them an amount equal to $16.66 2/3 in cash plus 0.010030 ordinary shares, nominal value $0.0001 per share, of Jazz. The transaction is more fully described in the Company's definitive proxy statement filed with the Securities and Exchange Commission on March 15, 2021."}],"balance_after":0,"source":{"system":"sec-edgar","filing":"0000899243-21-018665","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1351288/000089924321018665/doc4.xml","form_type":"4"}},{"id":2835505,"issuer":{"id":139616,"kind":"organization","name":"GW PHARMACEUTICALS PLC","symbol":"GWPH"},"owners":[{"id":73055,"kind":"person","name":"Noble James","position":1,"cik":"0001388000","reported_name":"Noble James","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Share Options","published_at":"2021-02-24T18:44:13.000Z","date":"2021-02-22","kind":"grant","acquired":true,"shares":22464,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"security","element":"securityTitle","label":"F1","text":"Granted pursuant to the Issuer's Long-Term Incentive Plan"},{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F2","text":"Converted from British Pounds Sterling to U.S. Dollars using currency ratio of 1.00 British Pound Sterling = 1.41 U.S. Dollars as of February 22, 2021."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F3","text":"These share options will vest in three equal annual installments beginning on February 22, 2022."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F4","text":"Subject to accelerated vesting in connection with the closing of the transactions contemplated by the Transaction Agreement, dated as of February 3, 2021, by and among Jazz Pharmaceuticals UK Holdings Limited, Jazz Pharmaceuticals Public Limited Company and GW Pharmaceuticals plc."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F4","text":"Subject to accelerated vesting in connection with the closing of the transactions contemplated by the Transaction Agreement, dated as of February 3, 2021, by and among Jazz Pharmaceuticals UK Holdings Limited, Jazz Pharmaceuticals Public Limited Company and GW Pharmaceuticals plc."}],"balance_after":22464,"derivative":{"exercise_price":0.0014,"expiration_date":"2031-02-22","underlying":"Ordinary Shares","underlying_shares":22464},"source":{"system":"sec-edgar","filing":"0000899243-21-008083","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1351288/000089924321008083/doc4.xml","form_type":"4"}},{"id":3094932,"issuer":{"id":9824,"kind":"organization","name":"Adaptimmune Therapeutics PLC"},"owners":[{"id":73055,"kind":"person","name":"Noble James","position":1,"cik":"0001388000","reported_name":"Noble James","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Option to purchase Ordinary Shares","published_at":"2020-07-01T17:08:16.000Z","date":"2020-07-01","kind":"grant","acquired":true,"shares":179785,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F1","text":"The exercise price was converted from GBP1.35 based on an exchange rate of $U.S. 1.2387 to GBP1.00.  The actual exercise price will be the pounds sterling amount."}],"balance_after":179785,"derivative":{"exercise_price":1.67,"exercise_date":"2021-07-01","expiration_date":"2030-07-01","underlying":"Ordinary Shares","underlying_shares":179785},"source":{"system":"sec-edgar","filing":"0001104659-20-079787","document":"a4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1388000/000110465920079787/a4.xml","form_type":"4"}},{"id":3118523,"issuer":{"id":139616,"kind":"organization","name":"GW PHARMACEUTICALS PLC","symbol":"GWPH"},"owners":[{"id":73055,"kind":"person","name":"Noble James","position":1,"cik":"0001388000","reported_name":"Noble James","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Share Options","published_at":"2020-06-08T20:05:24.000Z","date":"2020-06-04","kind":"grant","acquired":true,"shares":34416,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"security","element":"securityTitle","label":"F1","text":"Granted pursuant to the Issuer's Long-Term Incentive Plan."},{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F2","text":"Converted from British Pounds Sterling to U.S. Dollars using currency ratio of 1.00 British Pound Sterling = 1.26 U.S. Dollars as of June 4, 2020."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F3","text":"These share options will vest in three equal annual installments beginning on June 4, 2021."}],"balance_after":34416,"derivative":{"exercise_price":0.0013,"expiration_date":"2030-06-04","underlying":"Ordinary Shares","underlying_shares":34416},"source":{"system":"sec-edgar","filing":"0000899243-20-015699","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1351288/000089924320015699/doc4.xml","form_type":"4"}},{"id":3126569,"issuer":{"id":9824,"kind":"organization","name":"Adaptimmune Therapeutics PLC"},"owners":[{"id":73055,"kind":"person","name":"Noble James","position":1,"cik":"0001388000","reported_name":"Noble James","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"American Depositary Shares","published_at":"2020-06-02T21:30:35.000Z","date":"2020-05-29","kind":"sale","acquired":false,"shares":500000,"price":9.332,"value":4666000.0,"ownership":{"direct":true},"footnotes":[{"field":"security","element":"securityTitle","label":"F1","text":"The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on June 28, 2019."},{"field":"shares","element":"transactionShares","label":"F3","text":"The ADSs reported in this Column 4 represent solely those ADSs that were sold pursuant to a Rule 10b5-1 trading plan. Additionally, the reporting person holds 8,145,700 ordinary shares and share options covering an aggregate of 9,137,960 ordinary shares of the Issuer."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"The price reported in Column 4 is a weighted average price. These ADSs were sold in multiple transactions at prices ranging from $9.02 to $10.13, inclusive. Upon request, the reporting person undertakes to provide the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission full information regarding the ADSs sold at this price in this footnote."}],"balance_after":0,"source":{"system":"sec-edgar","filing":"0001104659-20-069142","document":"a4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1388000/000110465920069142/a4.xml","form_type":"4"}},{"id":3188798,"issuer":{"id":9824,"kind":"organization","name":"Adaptimmune Therapeutics PLC"},"owners":[{"id":73055,"kind":"person","name":"Noble James","position":1,"cik":"0001388000","reported_name":"Noble James","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Option to purchase Ordinary Shares","published_at":"2020-04-01T19:06:41.000Z","date":"2020-04-01","kind":"grant","acquired":true,"shares":31000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F1","text":"The exercise price was converted from GBP0.36 based on an exchange rate of $U.S. 1.245481 to GBP1.00.  The actual exercise price will be the pounds sterling amount."}],"balance_after":31000,"derivative":{"exercise_price":0.45,"exercise_date":"2021-04-01","expiration_date":"2030-04-01","underlying":"Ordinary Shares","underlying_shares":31000},"source":{"system":"sec-edgar","filing":"0001104659-20-042013","document":"a4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1388000/000110465920042013/a4.xml","form_type":"4"}},{"id":3310599,"issuer":{"id":9824,"kind":"organization","name":"Adaptimmune Therapeutics PLC"},"owners":[{"id":73055,"kind":"person","name":"Noble James","position":1,"cik":"0001388000","reported_name":"Noble James","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"American Depositary Shares","published_at":"2020-01-15T20:01:30.000Z","date":"2020-01-13","kind":"sale","acquired":false,"shares":200000,"price":5,"value":1000000.0,"ownership":{"direct":true},"footnotes":[{"field":"security","element":"securityTitle","label":"F1","text":"The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on June 28, 2019."},{"field":"price","element":"transactionPricePerShare","label":"F3","text":"These ADSs were sold in multiple transactions at a price of $5.00. Upon request, the reporting person undertakes to provide the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission full information regarding the ADSs sold at this price in this footnote."}],"balance_after":0,"source":{"system":"sec-edgar","filing":"0001104659-20-004419","document":"a4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1388000/000110465920004419/a4.xml","form_type":"4"}},{"id":3310598,"issuer":{"id":9824,"kind":"organization","name":"Adaptimmune Therapeutics PLC"},"owners":[{"id":73055,"kind":"person","name":"Noble James","position":1,"cik":"0001388000","reported_name":"Noble James","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"American Depositary Shares","published_at":"2020-01-15T20:01:30.000Z","date":"2020-01-13","kind":"sale","acquired":false,"shares":100000,"price":4,"value":400000.0,"ownership":{"direct":true},"footnotes":[{"field":"security","element":"securityTitle","label":"F1","text":"The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on June 28, 2019."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"These ADSs were sold in multiple transactions at a price of $4.00. Upon request, the reporting person undertakes to provide the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission full information regarding the ADSs sold at this price in this footnote."}],"balance_after":0,"source":{"system":"sec-edgar","filing":"0001104659-20-004419","document":"a4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1388000/000110465920004419/a4.xml","form_type":"4"}},{"id":3508605,"issuer":{"id":139616,"kind":"organization","name":"GW PHARMACEUTICALS PLC","symbol":"GWPH"},"owners":[{"id":73055,"kind":"person","name":"Noble James","position":1,"cik":"0001388000","reported_name":"Noble James","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Options","published_at":"2019-05-29T20:00:23.000Z","date":"2019-05-24","kind":"exercise","acquired":false,"shares":34056,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F2","text":"Converted from British Pounds Sterling to U.S. Dollars using currency ratio of 1.00 British Pound Sterling = 1.27 U.S. Dollars as of May 24, 2019."}],"balance_after":5,"derivative":{"exercise_price":4.8641,"exercise_date":"2018-12-29","expiration_date":"2025-12-29","underlying":"Ordinary Shares","underlying_shares":34056},"source":{"system":"sec-edgar","filing":"0000899243-19-015096","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":10,"url":"https://www.sec.gov/Archives/edgar/data/1351288/000089924319015096/doc4.xml","form_type":"4"}},{"id":3508604,"issuer":{"id":139616,"kind":"organization","name":"GW PHARMACEUTICALS PLC","symbol":"GWPH"},"owners":[{"id":73055,"kind":"person","name":"Noble James","position":1,"cik":"0001388000","reported_name":"Noble James","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Options","published_at":"2019-05-29T20:00:23.000Z","date":"2019-05-24","kind":"exercise","acquired":false,"shares":34061,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F2","text":"Converted from British Pounds Sterling to U.S. Dollars using currency ratio of 1.00 British Pound Sterling = 1.27 U.S. Dollars as of May 24, 2019."}],"balance_after":0,"derivative":{"exercise_price":4.8641,"exercise_date":"2018-12-29","expiration_date":"2025-12-29","underlying":"Ordinary Shares","underlying_shares":34061},"source":{"system":"sec-edgar","filing":"0000899243-19-015096","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":9,"url":"https://www.sec.gov/Archives/edgar/data/1351288/000089924319015096/doc4.xml","form_type":"4"}},{"id":3508603,"issuer":{"id":139616,"kind":"organization","name":"GW PHARMACEUTICALS PLC","symbol":"GWPH"},"owners":[{"id":73055,"kind":"person","name":"Noble James","position":1,"cik":"0001388000","reported_name":"Noble James","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Options","published_at":"2019-05-29T20:00:23.000Z","date":"2019-05-24","kind":"exercise","acquired":false,"shares":14479,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F2","text":"Converted from British Pounds Sterling to U.S. Dollars using currency ratio of 1.00 British Pound Sterling = 1.27 U.S. Dollars as of May 24, 2019."}],"balance_after":0,"derivative":{"exercise_price":0.0013,"exercise_date":"2018-12-29","expiration_date":"2025-12-29","underlying":"Ordinary Shares","underlying_shares":14479},"source":{"system":"sec-edgar","filing":"0000899243-19-015096","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":8,"url":"https://www.sec.gov/Archives/edgar/data/1351288/000089924319015096/doc4.xml","form_type":"4"}},{"id":3508602,"issuer":{"id":139616,"kind":"organization","name":"GW PHARMACEUTICALS PLC","symbol":"GWPH"},"owners":[{"id":73055,"kind":"person","name":"Noble James","position":1,"cik":"0001388000","reported_name":"Noble James","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Ordinary Shares","published_at":"2019-05-29T20:00:23.000Z","date":"2019-05-24","kind":"sale","acquired":false,"shares":13800,"price":15.58,"value":215004.0,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F3","text":"Represented by ADSs. The sales reported were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on May 9, 2019."},{"field":"price","element":"transactionPricePerShare","label":"F8","text":"The price reported in Column 4 is a weighted average price per ordinary share ($186.99 per ADS). These shares were sold in multiple transactions at prices ranging from $186.58 per ADS (or $15.55 per ordinary share) to $187.43 per ADS (or $15.62 per ordinary share), inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range."}],"balance_after":27500,"source":{"system":"sec-edgar","filing":"0000899243-19-015096","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":7,"url":"https://www.sec.gov/Archives/edgar/data/1351288/000089924319015096/doc4.xml","form_type":"4"}},{"id":3508601,"issuer":{"id":139616,"kind":"organization","name":"GW PHARMACEUTICALS PLC","symbol":"GWPH"},"owners":[{"id":73055,"kind":"person","name":"Noble James","position":1,"cik":"0001388000","reported_name":"Noble James","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Ordinary Shares","published_at":"2019-05-29T20:00:23.000Z","date":"2019-05-24","kind":"sale","acquired":false,"shares":3600,"price":15.49,"value":55764.0,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F3","text":"Represented by ADSs. The sales reported were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on May 9, 2019."},{"field":"price","element":"transactionPricePerShare","label":"F7","text":"The price reported in Column 4 is a weighted average price per ordinary share ($185.88 per ADS). These shares were sold in multiple transactions at prices ranging from $185.40 per ADS (or $15.45 per ordinary share) to $186.20 per ADS (or $15.52 per ordinary share), inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range."}],"balance_after":41300,"source":{"system":"sec-edgar","filing":"0000899243-19-015096","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":6,"url":"https://www.sec.gov/Archives/edgar/data/1351288/000089924319015096/doc4.xml","form_type":"4"}},{"id":3508600,"issuer":{"id":139616,"kind":"organization","name":"GW PHARMACEUTICALS PLC","symbol":"GWPH"},"owners":[{"id":73055,"kind":"person","name":"Noble James","position":1,"cik":"0001388000","reported_name":"Noble James","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Ordinary Shares","published_at":"2019-05-29T20:00:23.000Z","date":"2019-05-24","kind":"sale","acquired":false,"shares":10200,"price":15.32,"value":156264.0,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F3","text":"Represented by ADSs. The sales reported were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on May 9, 2019."},{"field":"price","element":"transactionPricePerShare","label":"F6","text":"The price reported in Column 4 is a weighted average price per ordinary share ($183.78 per ADS). These shares were sold in multiple transactions at prices ranging from $183.58 per ADS (or $15.30 per ordinary share) to $184.15 per ADS (or $15.35 per ordinary share), inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range."}],"balance_after":44900,"source":{"system":"sec-edgar","filing":"0000899243-19-015096","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":5,"url":"https://www.sec.gov/Archives/edgar/data/1351288/000089924319015096/doc4.xml","form_type":"4"}},{"id":3508599,"issuer":{"id":139616,"kind":"organization","name":"GW PHARMACEUTICALS PLC","symbol":"GWPH"},"owners":[{"id":73055,"kind":"person","name":"Noble James","position":1,"cik":"0001388000","reported_name":"Noble James","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Ordinary Shares","published_at":"2019-05-29T20:00:23.000Z","date":"2019-05-24","kind":"sale","acquired":false,"shares":41796,"price":15.26,"value":637806.96,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F3","text":"Represented by ADSs. The sales reported were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on May 9, 2019."},{"field":"price","element":"transactionPricePerShare","label":"F5","text":"The price reported in Column 4 is a weighted average price per ordinary share ($183.18 per ADS). These shares were sold in multiple transactions at prices ranging from $182.58 per ADS (or $15.22 per ordinary share) to $183.54 per ADS (or $15.30 per ordinary share), inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range."}],"balance_after":55100,"source":{"system":"sec-edgar","filing":"0000899243-19-015096","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":4,"url":"https://www.sec.gov/Archives/edgar/data/1351288/000089924319015096/doc4.xml","form_type":"4"}},{"id":3508598,"issuer":{"id":139616,"kind":"organization","name":"GW PHARMACEUTICALS PLC","symbol":"GWPH"},"owners":[{"id":73055,"kind":"person","name":"Noble James","position":1,"cik":"0001388000","reported_name":"Noble James","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Ordinary Shares","published_at":"2019-05-29T20:00:23.000Z","date":"2019-05-24","kind":"sale","acquired":false,"shares":13200,"price":15.17,"value":200244.0,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F3","text":"Represented by ADSs. The sales reported were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on May 9, 2019."},{"field":"price","element":"transactionPricePerShare","label":"F4","text":"The price reported in Column 4 is a weighted average price per ordinary share ($182.00 per ADS). These shares were sold in multiple transactions at prices ranging from $181.56 per ADS (or $15.13 per ordinary share) to $182.54 per ADS (or $15.21 per ordinary share), inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range."}],"balance_after":96896,"source":{"system":"sec-edgar","filing":"0000899243-19-015096","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1351288/000089924319015096/doc4.xml","form_type":"4"}},{"id":3508597,"issuer":{"id":139616,"kind":"organization","name":"GW PHARMACEUTICALS PLC","symbol":"GWPH"},"owners":[{"id":73055,"kind":"person","name":"Noble James","position":1,"cik":"0001388000","reported_name":"Noble James","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Ordinary Shares","published_at":"2019-05-29T20:00:23.000Z","date":"2019-05-24","kind":"exercise","acquired":true,"shares":68117,"price":4.8641,"value":331327.8997,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"Exercise of stock options. Following the exercise, these shares were converted into American Depositary Shares (\"ADS\") of the Issuer. Each ADS represents twelve ordinary shares of the Issuer."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"Converted from British Pounds Sterling to U.S. Dollars using currency ratio of 1.00 British Pound Sterling = 1.27 U.S. Dollars as of May 24, 2019."}],"balance_after":110096,"source":{"system":"sec-edgar","filing":"0000899243-19-015096","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1351288/000089924319015096/doc4.xml","form_type":"4"}},{"id":3508596,"issuer":{"id":139616,"kind":"organization","name":"GW PHARMACEUTICALS PLC","symbol":"GWPH"},"owners":[{"id":73055,"kind":"person","name":"Noble James","position":1,"cik":"0001388000","reported_name":"Noble James","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Ordinary Shares","published_at":"2019-05-29T20:00:23.000Z","date":"2019-05-24","kind":"exercise","acquired":true,"shares":14479,"price":0.0013,"value":18.8227,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"Exercise of stock options. Following the exercise, these shares were converted into American Depositary Shares (\"ADS\") of the Issuer. Each ADS represents twelve ordinary shares of the Issuer."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"Converted from British Pounds Sterling to U.S. Dollars using currency ratio of 1.00 British Pound Sterling = 1.27 U.S. Dollars as of May 24, 2019."}],"balance_after":41979,"source":{"system":"sec-edgar","filing":"0000899243-19-015096","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1351288/000089924319015096/doc4.xml","form_type":"4"}},{"id":3520254,"issuer":{"id":9824,"kind":"organization","name":"Adaptimmune Therapeutics PLC"},"owners":[{"id":73055,"kind":"person","name":"Noble James","position":1,"cik":"0001388000","reported_name":"Noble James","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Executive Officer"}}],"security":"Ordinary Shares with a nominal value of GBP0.001 per share","published_at":"2019-05-17T18:00:33.000Z","date":"2019-05-16","kind":"exercise","acquired":true,"shares":1773100,"price":0.143,"value":253553.3,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"The ordinary shares whose purchase is reported on this line were obtained from the exercise of share options that were granted on March 20, 2015. The ordinary shares continue to be held by the Reporting Person."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"The price reported in Column 4 of $0.143 per ordinary share is derived from the option purchase price paid on May 16, 2019 of GBP 0.112 per ordinary share."},{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F1","text":"The ordinary shares whose purchase is reported on this line were obtained from the exercise of share options that were granted on March 20, 2015. The ordinary shares continue to be held by the Reporting Person."}],"balance_after":1773100,"source":{"system":"sec-edgar","filing":"0001104659-19-030337","document":"a4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1388000/000110465919030337/a4.xml","form_type":"4"}},{"id":3611690,"issuer":{"id":139616,"kind":"organization","name":"GW PHARMACEUTICALS PLC","symbol":"GWPH"},"owners":[{"id":73055,"kind":"person","name":"Noble James","position":1,"cik":"0001388000","reported_name":"Noble James","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Options","published_at":"2019-03-05T21:05:52.000Z","date":"2019-03-01","kind":"grant","acquired":true,"shares":3144,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"security","element":"securityTitle","label":"F1","text":"Granted pursuant to the Issuer's Long-Term Incentive Plan."},{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F4","text":"Converted from British Pounds Sterling to U.S. Dollars using currency ratio of 1.00 British Pound Sterling = 1.32 U.S. Dollars as of March 1, 2019."}],"balance_after":3144,"derivative":{"exercise_price":0.0013,"exercise_date":"2022-03-01","expiration_date":"2029-03-01","underlying":"Ordinary Shares","underlying_shares":3144},"source":{"system":"sec-edgar","filing":"0000899243-19-006333","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":4,"url":"https://www.sec.gov/Archives/edgar/data/1351288/000089924319006333/doc4.xml","form_type":"4"}},{"id":3611689,"issuer":{"id":139616,"kind":"organization","name":"GW PHARMACEUTICALS PLC","symbol":"GWPH"},"owners":[{"id":73055,"kind":"person","name":"Noble James","position":1,"cik":"0001388000","reported_name":"Noble James","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Options","published_at":"2019-03-05T21:05:52.000Z","date":"2019-03-01","kind":"grant","acquired":true,"shares":3144,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"security","element":"securityTitle","label":"F1","text":"Granted pursuant to the Issuer's Long-Term Incentive Plan."},{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F4","text":"Converted from British Pounds Sterling to U.S. Dollars using currency ratio of 1.00 British Pound Sterling = 1.32 U.S. Dollars as of March 1, 2019."}],"balance_after":3144,"derivative":{"exercise_price":0.0013,"exercise_date":"2021-03-01","expiration_date":"2029-03-01","underlying":"Ordinary Shares","underlying_shares":3144},"source":{"system":"sec-edgar","filing":"0000899243-19-006333","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1351288/000089924319006333/doc4.xml","form_type":"4"}},{"id":3611688,"issuer":{"id":139616,"kind":"organization","name":"GW PHARMACEUTICALS PLC","symbol":"GWPH"},"owners":[{"id":73055,"kind":"person","name":"Noble James","position":1,"cik":"0001388000","reported_name":"Noble James","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Options","published_at":"2019-03-05T21:05:52.000Z","date":"2019-03-01","kind":"grant","acquired":true,"shares":3144,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"security","element":"securityTitle","label":"F1","text":"Granted pursuant to the Issuer's Long-Term Incentive Plan."},{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F4","text":"Converted from British Pounds Sterling to U.S. Dollars using currency ratio of 1.00 British Pound Sterling = 1.32 U.S. Dollars as of March 1, 2019."}],"balance_after":3144,"derivative":{"exercise_price":0.0013,"exercise_date":"2020-03-01","expiration_date":"2029-03-01","underlying":"Ordinary Shares","underlying_shares":3144},"source":{"system":"sec-edgar","filing":"0000899243-19-006333","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1351288/000089924319006333/doc4.xml","form_type":"4"}},{"id":3611687,"issuer":{"id":139616,"kind":"organization","name":"GW PHARMACEUTICALS PLC","symbol":"GWPH"},"owners":[{"id":73055,"kind":"person","name":"Noble James","position":1,"cik":"0001388000","reported_name":"Noble James","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Options","published_at":"2019-03-05T21:05:52.000Z","date":"2019-03-01","kind":"grant","acquired":true,"shares":16548,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"security","element":"securityTitle","label":"F1","text":"Granted pursuant to the Issuer's Long-Term Incentive Plan."},{"field":"security","element":"securityTitle","label":"F2","text":"The reported options are options to purchase American Depositary Shares of the Issuer (\"ADS\"). Each ADS represents twelve ordinary shares of the Issuer."},{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F3","text":"The exercise price reported is price per ordinary share converted from price per ADS ($172.01)."}],"balance_after":16548,"derivative":{"exercise_price":14.33,"exercise_date":"2022-03-01","expiration_date":"2029-03-01","underlying":"Ordinary Shares","underlying_shares":16548},"source":{"system":"sec-edgar","filing":"0000899243-19-006333","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1351288/000089924319006333/doc4.xml","form_type":"4"}},{"id":3699904,"issuer":{"id":9824,"kind":"organization","name":"Adaptimmune Therapeutics PLC"},"owners":[{"id":73055,"kind":"person","name":"Noble James","position":1,"cik":"0001388000","reported_name":"Noble James","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Executive Officer"}}],"security":"Option to purchase Ordinary Shares","published_at":"2019-01-08T21:00:53.000Z","date":"2019-01-04","kind":"grant","acquired":true,"shares":561792,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F3","text":"The exercise price was converted from GBP0.001, being the nominal value of an ordinary share, based on an exchange rate of $U.S. 1.26332 - GBP1.00. The actual exercise price will be the pounds sterling amount."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F4","text":"Exercisable as to 140,448 Ordinary Shares on January 4, 2020 and will be exercisable as to the remainder in annual installments of 140,448 Ordinary Shares on the fourth of each January from January 4, 2021 through January 4, 2023."}],"balance_after":561792,"derivative":{"exercise_price":0.0013,"expiration_date":"2029-01-04","underlying":"Ordinary Shares","underlying_shares":561792},"source":{"system":"sec-edgar","filing":"0001104659-19-001300","document":"a4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1388000/000110465919001300/a4.xml","form_type":"4"}},{"id":3699903,"issuer":{"id":9824,"kind":"organization","name":"Adaptimmune Therapeutics PLC"},"owners":[{"id":73055,"kind":"person","name":"Noble James","position":1,"cik":"0001388000","reported_name":"Noble James","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Executive Officer"}}],"security":"Option to purchase Ordinary Shares","published_at":"2019-01-08T21:00:53.000Z","date":"2019-01-04","kind":"grant","acquired":true,"shares":2515536,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F1","text":"The exercise price was converted from GBP0.70 based on an exchange rate of $U.S. 1.26332 - GBP1.00.  The actual exercise price will be the pounds sterling amount."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"Exercisable as to 628,884 Ordinary Shares on January 4, 2020 and will be exercisable as to the remainder in monthly installments of 52,404 Ordinary Shares on the fourth of each month from February 4, 2020 through December 4, 2022 and 52,512 Ordinary Shares on January 4, 2023."}],"balance_after":2515536,"derivative":{"exercise_price":0.89,"expiration_date":"2029-01-04","underlying":"Ordinary Shares","underlying_shares":2515536},"source":{"system":"sec-edgar","filing":"0001104659-19-001300","document":"a4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1388000/000110465919001300/a4.xml","form_type":"4"}},{"id":4097535,"issuer":{"id":9824,"kind":"organization","name":"Adaptimmune Therapeutics PLC"},"owners":[{"id":73055,"kind":"person","name":"Noble James","position":1,"cik":"0001388000","reported_name":"Noble James","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Executive Officer"}}],"security":"Option to purchase Ordinary Shares","published_at":"2018-01-17T17:20:06.000Z","date":"2018-01-12","kind":"grant","acquired":true,"shares":384120,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F3","text":"The exercise price was converted from GBP0.001, being the nominal value of an ordinary share, based on an exchange rate of $U.S. 1.3542 - GBP1.00. The actual exercise price will be the pounds sterling amount."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F4","text":"Exercisable as to 96,030 Ordinary Shares on January 12, 2019 and will be exercisable as to the remainder in annual installments of 96,030 Ordinary Shares on the twelfth of each January from January 12, 2020 through January 12, 2022."}],"balance_after":384120,"derivative":{"exercise_price":0.0014,"expiration_date":"2028-01-12","underlying":"Ordinary Shares","underlying_shares":384120},"source":{"system":"sec-edgar","filing":"0001104659-18-002673","document":"a4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1388000/000110465918002673/a4.xml","form_type":"4"}},{"id":4097534,"issuer":{"id":9824,"kind":"organization","name":"Adaptimmune Therapeutics PLC"},"owners":[{"id":73055,"kind":"person","name":"Noble James","position":1,"cik":"0001388000","reported_name":"Noble James","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Executive Officer"}}],"security":"Option to purchase Ordinary Shares","published_at":"2018-01-17T17:20:06.000Z","date":"2018-01-12","kind":"grant","acquired":true,"shares":1719936,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F1","text":"The exercise price was converted from GBP0.96 based on an exchange rate of $U.S. 1.3542 - GBP1.00.  The actual exercise price will be the pounds sterling amount."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"Exercisable as to 429,984 Ordinary Shares on January 12, 2019 and will be exercisable as to the remainder in monthly installments of 35,832 Ordinary Shares on the twelfth of each month from February 12, 2019 through January 12, 2022."}],"balance_after":1719936,"derivative":{"exercise_price":1.3,"expiration_date":"2028-01-12","underlying":"Ordinary Shares","underlying_shares":1719936},"source":{"system":"sec-edgar","filing":"0001104659-18-002673","document":"a4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1388000/000110465918002673/a4.xml","form_type":"4"}},{"id":4487927,"issuer":{"id":9824,"kind":"organization","name":"Adaptimmune Therapeutics PLC"},"owners":[{"id":73055,"kind":"person","name":"Noble James","position":1,"cik":"0001388000","reported_name":"Noble James","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Executive Officer"}}],"security":"Option to purchase Ordinary Shares","published_at":"2017-01-18T17:00:46.000Z","date":"2017-01-13","kind":"grant","acquired":true,"shares":2072976,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F1","text":"The exercise price was converted from GBP0.59 based on the closing midpoint exchange rate for the U.S. dollar on the day prior to the date of grant listed in the Financial Times. The actual exercise price will be the pounds sterling amount."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"Exercisable as to 518,244 Ordinary Shares on January 13, 2018 and will be exercisable as to the remainder in monthly installments of 43,187 Ordinary Shares on the thirteenth of each month from February 13, 2018 through January 13, 2021."}],"balance_after":2072976,"derivative":{"exercise_price":0.72,"expiration_date":"2027-01-13","underlying":"Ordinary Shares","underlying_shares":2072976},"source":{"system":"sec-edgar","filing":"0001104659-17-002818","document":"a4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1388000/000110465917002818/a4.xml","form_type":"4"}}]}